Last reviewed 2026-04-20 · How we verify

Falignost (IOMEGLAMIC ACID)

Phase 2 active Small molecule

Falignost (generic name: IOMEGLAMIC ACID) is a iomeglamic acid drug. It is currently in Phase 2 development.

Unfortunately, the mechanism of action for iomeglamic acid is not available.

Iomeglamic acid is a small molecule drug of the iomeglamic acid class, but specific details about its development, commercial status, and approved indications are not available. As a result, there is limited information about its target, half-life, bioavailability, and generic manufacturers. The mechanism of action and key safety considerations for iomeglamic acid are also unknown. Further research is needed to understand its pharmacological properties and clinical applications. Unfortunately, without more information, it is challenging to provide a comprehensive summary of this drug.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	IOMEGLAMIC ACID
Drug class	iomeglamic acid
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

The mechanism of action for iomeglamic acid is not available, but in general, small molecule drugs like iomeglamic acid work by interacting with specific biological targets, such as proteins or receptors, to produce a therapeutic effect. This interaction can alter the activity of the target, leading to changes in the body's physiological processes. However, without more information about iomeglamic acid, it is impossible to provide a detailed explanation of its mechanism of action.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Falignost CI brief — competitive landscape report
Falignost updates RSS · CI watch RSS

Frequently asked questions about Falignost

What is Falignost?

Falignost (IOMEGLAMIC ACID) is a iomeglamic acid drug.

How does Falignost work?

Unfortunately, the mechanism of action for iomeglamic acid is not available.

What is the generic name of Falignost?

IOMEGLAMIC ACID is the generic (nonproprietary) name of Falignost.

What drug class is Falignost in?

Falignost belongs to the iomeglamic acid class. See all iomeglamic acid drugs at /class/iomeglamic-acid.

What development phase is Falignost in?

Falignost is in Phase 2.

Drug class: All iomeglamic acid drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing